A 2026 review explored whether cannabigerol (CBG), a non-intoxicating cannabinoid, may influence biological processes involved in drug-resistant epilepsy. Rather than focusing only on seizure suppression, the authors examined CBG’s potential effects on neuroinflammation, oxidative stress, mitochondrial dysfunction, blood-brain barrier disruption, and neurodegeneration—processes increasingly recognized as contributing to the development and persistence of epilepsy.

CBG interacts with multiple biological targets, including cannabinoid receptors, adrenergic receptors, serotonin receptors, and transient receptor potential channels. Preclinical research suggests these interactions may contribute to anti-inflammatory, antioxidant, and neuroprotective effects. The authors propose that these mechanisms could make CBG worth investigating as a possible disease-modifying compound in drug-resistant epilepsy, potentially complementing approaches that primarily target seizures.

The review is hypothesis-generating and does not provide clinical evidence that CBG can treat epilepsy. The authors emphasize that CBG’s effects on seizure activity, drug resistance, and epilepsy-related brain changes have not yet been adequately established experimentally. More laboratory, animal, and eventually clinical studies are needed to determine whether CBG has a meaningful therapeutic role in people with drug-resistant epilepsy.

Source: Patricio-Martínez A, Hernández-Percastegui S, Tzompantzi Juarez NT, Patricio F, Limón ID. Elucidating the putative role of cannabigerol: a hypothesis-generating review of neuroinflammatory and neuroprotective mechanisms with implications for drug-resistant epilepsy. Frontiers in Pharmacology. 2026;17:1755956. DOI: 10.3389/fphar.2026.1755956. PMID: 41919226. https://pubmed.ncbi.nlm.nih.gov/41919226/